Adagene Inc. is a platform driven clinical stage biotechnology company focused on discovering and developing antibody based cancer immunotherapies. The company leverages its proprietary Dynamic Precision Library DPL platform together with three technology platforms NEObody SAFEbody and POWERbody to design novel antibodies that can be activated selectively in the tumor microenvironment. Its lead candidate ADG126 is a masked anti CTLA 4 antibody currently in phase 1b/2 and phase 2 clinical trials for metastatic microsatellite stable colorectal cancer. In addition Adagene Inc. advances earlier stage programs such as ADG206 an Fc enhanced anti CD137 antibody and several IND ready candidates built on its platform technologies. The company also maintains a robust pipeline of earlier stage candidates that apply its NEObody and SAFEbody technologies to targets such as HER2 and CD47 expanding its therapeutic reach beyond immuno oncology.

Adagene Inc. generates revenue primarily through technology licensing and collaboration agreements with pharmaceutical partners as well as through out licensed product candidate rights. The company receives upfront payments milestone payments and royalties on net sales from agreements with companies such as Sanofi Exelixis Third Arc Bio and ConjugateBio. In 2022 the company received a three million dollar milestone from Exelixis upon achieving a preclinical development target and in 2023 another three million dollar milestone was earned for further progress. It has also out licensed the Greater China rights of ADG104 and ADG125 to Sanjin and Dragon Boat respectively which provide additional potential royalty streams. These arrangements offset research and development expenses and create future cash flow opportunities.

Adagene Inc. operates in the highly competitive immuno oncology sector where it faces established therapies and numerous early stage competitors. In the anti CTLA 4 space its rivals include marketed drugs such as Yervoy ipilimumab from Bristol Myers Squibb and Imjudo tremelimumab from AstraZeneca as well as clinical stage candidates from Agenus Merck Onco C4 and Xilio. For anti CD137 programs competitors include Pfizer’s utomilumab and Bristol Myers Squibb’s urelumab among others. Adagene’s competitive advantages stem from its DPL platform which enables rapid discovery of highly specific species cross reactive antibodies and from its three proprietary technologies that aim to improve safety profiles while maintaining potency. Its masked antibody approach aims to reduce off target toxicity while preserving tumor specific activity a differentiation that addresses a key limitation of conventional checkpoint inhibitors. The company’s strategic collaborations with large pharma firms further validate its technology and expand its reach.

Adagene Inc. serves patients who may eventually receive its investigational therapies while its current revenue comes from collaborations with biopharmaceutical companies. Key partners include Sanofi Exelixis Third Arc Bio ConjugateBio Sanjin and Dragon Boat. The company also works with academic and research institutions such as the National University Cancer Institute in Singapore and Roche for clinical trials. These relationships provide the customer base that supports its development pipeline and future commercialization. These collaborations span North America Europe and Asia reflecting the company’s global partnership strategy.